Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
about
Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-RitonavirPopulation Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 StudiesDrug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus LamivudineHepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection.Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.Clinical Pharmacokinetics of Ombitasvir.Clinical Pharmacokinetics of Paritaprevir.Clinical Pharmacokinetics of Dasabuvir.Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin.Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016.
P2860
Q36438920-C7A82DAD-6A4D-408D-9088-27C8D8AC30F2Q36445132-ACCF8645-B60B-4B3A-A0B0-0DE655292592Q37067118-18C09083-CBD9-4603-8303-9D1E20D317F6Q37287684-D269353C-87BC-4CAB-9621-008972E3405BQ37578288-900BFBB7-8D2A-43BA-9F5D-E599FE546859Q38393581-D9BB6915-ACD0-444E-B766-D355F04785C2Q38821075-45C3DB85-4E3C-4AC8-B4B0-E686A368CA73Q38927209-2B016CFD-C0CB-431D-A373-08A7D236D526Q39147495-E2EA710D-C776-4F96-9B47-C59F7C5161FBQ39150134-669E7314-F3E2-471F-AEC2-7FB4B093D589Q39160612-3FD0AB04-91A7-4F16-ABB7-9B611D5D9E06Q39357557-666D2040-BD26-46FF-B6B0-68324B212943Q39900651-410E06B2-CA76-466A-B8D6-9DCBFF2DB6EBQ40597366-7FD27169-C930-4EA4-9A29-EA565730D970Q40697687-102D1B89-6ADF-456F-AF87-4BAA94BF9F83Q55093102-84953D91-19C8-49D7-9ED7-233E728D9FC7
P2860
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
@ast
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
@en
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
@nl
type
label
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
@ast
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
@en
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
@nl
prefLabel
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
@ast
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
@en
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
@nl
P2093
P2860
P921
P1476
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy
@en
P2093
Akshanth R. Polepally
Barbara H. McGovern
Jennifer R. King
Prajakta S. Badri
Rajeev M. Menon
Sandeep Dutta
P2860
P2888
P304
P356
10.1007/S40262-015-0317-8
P407
P5008
P577
2016-03-01T00:00:00Z
P5875
P6179
1038693879